Computer-Aided Identification of Kinase-Targeted Small Molecules for Cancer: A Review on AKT Protein

Pharmaceuticals (Basel). 2023 Jul 11;16(7):993. doi: 10.3390/ph16070993.

Abstract

AKT (also known as PKB) is a serine/threonine kinase that plays a pivotal regulatory role in the PI3K/AKT/mTOR signaling pathway. Dysregulation of AKT activity, especially its hyperactivation, is closely associated with the development of various human cancers and resistance to chemotherapy. Over the years, a wide array of AKT inhibitors has been discovered through experimental and computational approaches. In this regard, herein we present a comprehensive overview of AKT inhibitors identified using computer-assisted drug design methodologies (including docking-based and pharmacophore-based virtual screening, machine learning, and quantitative structure-activity relationships) and successfully validated small molecules endowed with anticancer activity. Thus, this review provides valuable insights to support scientists focused on AKT inhibition for cancer treatment and suggests untapped directions for future computer-aided drug discovery efforts.

Keywords: AKT; QSAR; cancer; computer-aided drug discovery; docking; kinase inhibitors; machine learning; pharmacophore; virtual screening.

Publication types

  • Review

Grants and funding

This research received no external funding.